Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Novel chimeric monoclonal antibody offers hope in refractory colorectal cancer

01 Aug 2020

Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.

The study included 63 patients with advanced, refractory cancer who expressed MUC5AC antigen in tumour tissue (median age, 58 years; 54 percent male). The mean time from initial diagnosis to study entry was 3.79 years, and all patients had undergone a median of three prior cancer-directed therapies.

All patients received infusions of ensituximab at 3 mg/kg every 2 weeks. Among 57 patients (90 percent) who were evaluable, the median overall survival (OS) was 6.8 months and longer than the 5.0 months observed in the historical control (p=0.007). Twelve patients (21 percent) achieved stable disease (SD) at the end of the first treatment course. Forty-nine patients were evaluable for progression-free survival, which had a mean duration of 70.4 days.

The study drug was well tolerated. Commonly reported treatment-related adverse events (AEs) were fatigue (38 percent), anaemia (30 percent), nausea (15 percent), vomiting (11 percent), increased bilirubin (9 percent), constipation (8 percent), decreased appetite (6 percent), and diarrhoea (6 percent).

Serious AEs potentially related to ensituximab occurred in four patients and included anaemia, nausea, increased bilirubin, and hypoxia. None of the patients discontinued treatment due to drug-related AEs.

The present data provide supporting rationale for investigating combination therapies containing ensituximab plus interleukin-15 or other agents, such as chemotherapy, to boost efficacy in the patient population, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Jairia Dela Cruz, 23 Sep 2020
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.